Pacira BioSciences (NASDAQ:PCRX) Sees Unusually-High Trading Volume Following Analyst Upgrade

Key Points

• Pacira shares saw unusually high trading volume after JPMorgan upgraded the stock from underweight to neutral and set a $36.50 price target; about 845,298 shares traded, up 5% from the prior session.
• Viatris has agreed to acquire Pacira for $36.50 per share in cash, valuing the company at approximately $1.65 billion, with closing expected by the end of 2026. The deal has driven the stock sharply higher and leaves limited upside beyond the offer price.
• Analyst views remain mixed, with two Buy ratings, seven Holds, and two Sells and an average target of $31.44. Pacira’s latest quarterly results exceeded expectations, with adjusted EPS of $0.73 and revenue of $192.4 million, up 6.2% year over year.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) shares saw an uptick in trading volume on Friday after JPMorgan Chase & Co. upgraded the stock from an underweight rating to a neutral rating. JPMorgan Chase & Co. now has a $36.50 price target on the stock. Approximately 845,298 shares were traded during trading, an increase of 5% from the previous session's volume of 808,356 shares. The stock last traded at $36.3150 and had previously closed at $36.39.

A number of other research firms have also recently weighed in on PCRX. Royal Bank Of Canada upped their price target on Pacira BioSciences from $24.00 to $25.00 and gave the stock a "sector perform" rating in a report on Wednesday, August 5th. Zacks Research downgraded shares of Pacira BioSciences from a "hold" rating to a "strong sell" rating in a research note on Monday. Wall Street Zen upgraded shares of Pacira BioSciences from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 26th. Oppenheimer initiated coverage on Pacira BioSciences in a research note on Wednesday, September 23rd. They set an "outperform" rating and a $32.00 target price for the company. Finally, Truist Financial boosted their price target on Pacira BioSciences from $30.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday. Two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $31.44.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $23.23, for a total transaction of $70,619.20. Following the transaction, the insider directly owned 216,384 shares in the company, valued at $5,026,600.32. This represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by corporate insiders.

Trending Headlines about Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris acquisition provides a clear cash exit. Viatris will acquire Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders near-term deal certainty and values Pacira’s EXPAREL and ZILRETTA non-opioid pain medicines as strategic additions to Viatris’ portfolio. Closing is expected by the end of 2026. Viatris Agrees to Acquire Pacira BioSciences
• Positive Sentiment: Deal news triggered substantial buying. Reports indicated PCRX jumped about 44% and reached a 52-week high as investors repriced the shares toward Viatris’ $36.50 offer. Pacira BioSciences jumps on Viatris acquisition deal
• Neutral Sentiment: Analyst targets now largely reflect the transaction price. JPMorgan upgraded Pacira from underweight to neutral with a $36.50 target, while HC Wainwright reaffirmed neutral but reduced its target from $38 to $36.50. Jefferies maintained hold with a $36 target, and Needham cut its rating from buy to hold. These actions suggest limited fundamental upside beyond the proposed cash consideration.
• Neutral Sentiment: Truist raised its target to $31 and retained a buy rating, but the target is now below the current deal-related valuation. Pacira receives price target increase from Truist Financial
• Negative Sentiment: Shareholder law firms are investigating the transaction. Several firms are questioning whether the $36.50 offer fairly values Pacira, whether the board conducted an adequate sale process, and whether insiders received improper benefits. Such reviews could create legal or closing uncertainty, although they do not currently change the announced offer.
• Negative Sentiment: Bearish options activity was also reported in PCRX, signaling some traders are positioning for limited downside or deal-related uncertainty. Stocks drawing bearish options activity

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in Pacira BioSciences by 15.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company's stock worth $85,000 after buying an additional 492 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Pacira BioSciences by 10.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 11,746 shares of the company's stock worth $268,000 after acquiring an additional 1,142 shares during the last quarter. State of Wyoming increased its holdings in shares of Pacira BioSciences by 10.2% in the 1st quarter. State of Wyoming now owns 12,298 shares of the company's stock worth $278,000 after acquiring an additional 1,143 shares during the period. Hsbc Holdings PLC lifted its position in Pacira BioSciences by 7.7% in the 4th quarter. Hsbc Holdings PLC now owns 18,416 shares of the company's stock valued at $479,000 after purchasing an additional 1,316 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new position in Pacira BioSciences during the 2nd quarter valued at about $51,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Price Performance

The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 103.76 and a beta of 0.25. The business's 50 day simple moving average is $25.37 and its 200-day simple moving average is $24.51.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The business had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. During the same period in the previous year, the firm posted $0.74 earnings per share. The business's revenue was up 6.2% on a year-over-year basis. Research analysts anticipate that Pacira BioSciences, Inc. will post 1.91 earnings per share for the current year.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company's portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.